You searched for "Breast" from the Body Image.

Stage	Phase	Principal Investigator	Study prefix	Study number	Title (click hyperlink for more information)
	Pilot	Swati Kulkarni, MD	I	99507	A Pilot Study of Flaxseed vs Aromatase Inhibitor Between Biopsy and Surgery: Breast Tumor Characteristics and Prognosis
	II	Ellis Levine, MD	PH	134408	A Double-Blind, Randomized Phase 2b Study of Sorafenib Compared to Placebo When Administered in Combination with Chemotherapy for Patients with Locally Advanced or Metastatic Breast Cancer That has Progressed During or After Bevacizumab Therapy
	Pilot	Swati Kulkarni, MD	I	81906	A Study Evaluating the Effect of Flaxseed on Biomarkers of Breast Cancer Risk
	III	Ellis Levine, MD	NCG	104707	(SWOG S0500) A Randomized Phase III Trial to Test the Strategy of Changing Therapy Versus Maintaining Therapy for Metastatic Breast Cancer Patients Who Have Elevated Circulating Tumor Cell Levels at First Follow-Up Assessment
I-III	III	Ellis Levine, MD	NCG	78106	(IBCSG 25-02 Tamoxifen and Exemestane Trial) A Phase III Trial Evaluating the Role of Exemestane Plus GnRH Analogue as Adjuvant Therapy for Premenopausal Women with Endocrine Responsive Breast Cancer
	III	Ellis Levine, MD	NCG	82606	(ECOG PACCT-1) Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning IndividuaLized Options for Treatment: The TAILORx Trial
	I-III	Ellis Levine, MD	NCG	81106	(SWOG S0307) Phase III Trial of Biphosphonates as Adjuvant Therapy for Primary Breast Cancer
	N/A	HongC	I	53005	Women's Health After Breast Cancer Study
	III	Ellis Levine, MD	NCG / CALGB	101207	(CALGB 40302) Endocrine Therapy With or Without Inhibition of EGF and HER2 Growth Factor Receptors: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Fulvestrant With or Without Lapatinib (GW572016) for Postmenopausal Women with Hormone Receptor Positive Advanced Breast Cancer
N/A	III	Ellis Levine, MD	NCG	14703	(CTSU IBCSG 24-02): A Phase III Trial Evaluating the Role of Ovarian Function Suppression and the Role of Exemestane as Adjuvant Therapies for Premenopausal Women with Endocrine Responsive Breast Cancer
N/A	Survey	Stephen Edge, MD	NCG / CALGB	14103	(CALGB 369901) Observational Cohort Study: Chemotherapy Decisions in Women Age 65 or Older with Operable, Newly Diagnosed Breast Cancer
	III		NCG	124707	A Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide followed by Paclitaxel with Bevacizumab or Placebo in Patients with Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer
	II	Grace Dy, MD	PH	127408	A Phase 2 Study to Assess the Safety and Preliminary Efficacy of ARRY-334543 with Capecitabine or Lapatinib with Capecitabine in Patients with Advanced Breast Cancer Following a Phase 1 Lead-In to Assess the Safety of ARRY-334543 with Capecitabine in Patients with Advanced Cancer
	III	Ellis Levine, MD	NCG	146708	(CALGB 40601) Randomized Phase III Trial of Paclitaxel Combined with Trastuzumab, Lapatinib, or Both as Neoadjuvant Treatment of HER2-Positive Primary Breast Cancer
	III	Stephen Edge, MD	NCG	150809	(CTSU NSABP B-43) A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma in Situ Resected by Lumpectomy
	III	Ellis Levine, MD	NCG	157709	(CALGB 40502) A Randomized Phase III Trial of Weekly Paclitaxel Compared to Weekly Nanoparticle Albumin Bound Nab-Paclitaxel or Ixabepilone Combined with Bevacizumab as First-Line Therapy for Locally Recurrent or Metastatic Breast Cancer
N/A	III	Ellis Levine, MD	NCG / CALGB	42704	(CALGB 40401) Phase III Trial of LHRH Analog Administration During Chemotherapy to Reduce Ovarian Failure Following Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer
	III	Ellis Levine, MD	NCG	130808	A Randomized, Multi-Centre, Open-Label, Phase III Study of Adjuvant Lapatinib, Trastuzumab, Their Sequence and Their Sequence in Patients with HER2/ErB2 Positive Primary Breast Cancer
	NT	Tracey OConner, MD	I	146508	Correlation of Doxorubicin and Doxorubicinal Levels with Carbonyl Reductase Genotypes in Patients Receiving Doxorubicin for Treatment of Breast Cancer
	III	Ellis Levine, MD	NCG	128908	E1105: A Randomized Phase III Double-Blind Placebo-Controlled Trial of First-line Chemotherapy and Trastuzumab With or Without Bevacizumab for Patients with HER-2/NEU Over-expressing Metastatic Breast Cancer (CLOSED with TX)
	Survey	Ellis Levine, MD	NCG / CALGB	69205	(CALGB 70301/CTSU C7031) Quality of Life, Employment and Informal Care Cost Analysis in Women Receiving Adjuvant Chemotherapy for Breast Cancer with 0-3 Positive Axillary Lymph Nodes. (CLOSED w/FOLLOW UP)
		Ellis Levine, MD	NCG	136308	(ANZ 0701 Co-SOFT) Cognitive Function Substudy:Investigating Cognitive Function for Patients Participating in the SOFT Trial in Selected Centers
	III	Ellis Levine, MD	NCG	101907	(NSABP B-42) A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women with Hormone Receptor Positive Breast Cancer

Total number of Clinical Trials found: 23

Return to Search page